New research from the University of Birmingham and University of Oxford reveals that prucalopride, a common laxative stimulating specific serotonin receptors, could help sharpen memory and attention in individuals with a history of depression, tackling the often-overlooked cognitive symptoms known as brain fog.
- Prucalopride activates serotonin receptors linked to cognition
- Trial participants showed faster, more accurate thinking and memory
- Drug was well tolerated with minimal side effects reported
What happened
Researchers studied a group of individuals who had experienced depressive episodes in the past. Participants took either 2mg of prucalopride or a placebo daily for seven to ten days. Various cognitive tests assessed their executive function, short- and long-term memory, and emotional processing before and after the treatment period.
Those receiving prucalopride outperformed the placebo group, showing significant improvements in task speed and accuracy. The drug works by stimulating 5-HT4 receptors in the gut and brain, which are thought to enhance neural circuits involved in learning and memory, particularly in the hippocampus and connected frontal brain areas.
Why it feels good
Brain fog and cognitive difficulties such as trouble thinking, planning, and memory issues are common complaints among people with depression, yet these symptoms often remain untreated. Prucalopride’s positive effects on cognition could provide relief by boosting brain processes underlying learning and memory.
The drug’s mechanism may involve increased release of neurotransmitters like acetylcholine and modulation of glutamate systems, both important for cognitive health. Participants generally tolerated the treatment well, with no serious gut issues reported, although a slight decrease in appetite was noted.
What to enjoy or watch next
While the initial results are promising, wider studies are needed to confirm benefits in older adults and those with more complex psychiatric backgrounds. This trial focused on young to middle-aged adults in depression remission, so future research may explore how prucalopride affects those with active symptoms or other mental health conditions.
Researchers continue investigating serotonin receptor agonists as a promising new avenue for addressing cognitive symptoms in mental illness, a challenging area where current treatments offer limited support. Expect to see further developments in this space that may lead to improved quality of life for many affected individuals.